drugset / Trial / NCT02863991
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
RandomizedSingle-groupOpen-labelTreatment
Summary
This was a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone in adults with relapsed/refractory multiple myeloma. The primary objective of this study was to evaluate the antitumor efficacy of ONC201. Note: This study was completed by predecessor company, Oncoceutics, Inc.
Timeline
- Start
- 2017-04-19
- Primary completion
- 2019-09-17
- Completion
- 2019-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dordaviprone | Small molecule | 375 mg | Oral |
| Subject | Dordaviprone | Small molecule | 625 mg | Oral |
| Background | Dexamethasone | Small molecule | 20 mg | — |